Freyr has recently won a strategic Regulatory services project from a leading India-based, global 700+ million biopharmaceutical company. The project reiterates Freyr’s ever-growing global expertise in offering highly cost-effective, and technology-enabled Regulatory solutions and services.
As part of the offerings, Freyr aims to support its India-based Biopharma client with an end-to-end regulatory strategy for New Chemical Entity (NCE) and Biosimilar products in the emerging LATAM markets like Brazil & Mexico within the short proposed timelines.
“Such niche and time-bound projects prove Freyr’s capability as an end-to-end Regulatory service provider in terms of meeting the complex demands of the global Regulatory landscape. Providing top-notch client service has always been our goal and we are happy to take the leap towards it with multi-geo assignments like this” said Rajiv Rangan, Co-CEO, Freyr.